{
    "info": {
        "nct_id": "NCT05060432",
        "official_title": "A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
        "inclusion_criteria": "* Provide a signed written informed consent for the trial\n* Have measurable disease, per RECIST v1.1\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 or 1.\n* Have adequate organ functions\n* Part 1A/1B/1C/1D/1E/1F: Have histologically or cytologically confirmed advanced or metastatic solid tumor for whom no standard treatment with survival benefit is available\n\nPart 1G (NSCLC):\n\n* Have a histologically confirmed or cytologically confirmed previously untreated stage IV OR stage III not amenable to curative chemoradiotherapy or surgery (AJCC 8th edition) nonsquamous NSCLC OR squamous NSCLC.\n* Are eligible to receive anti-PD(L)1 therapy combined with chemotherapy in first line metastatic setting\n\nPart 2 (H&N cancer)\n\n* Have histologically or cytologically confirmed recurrent advanced or metastatic head and neck squamous cell carcinoma considered incurable by local therapies\n* PD-L1 status positive\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Have received any anti-cancer therapy within 4 weeks prior to the first dose\n* Have received a live vaccine within 30 days prior to the first dose\n* Have known primary CNS cancer.\n* Have known CNS metastases unless previously treated and well controlled for at least 1 month\n* Have concomitant second malignancies unless a complete remission was achieved at least 2 years before study entry\n* Have a history of Grade ≥ 2 pneumonitis, active autoimmune disease, or persistent immune-mediated toxicity caused by immune checkpoint inhibitor therapy of Grade ≥ 2\n* Have toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.\n* Have uncontrolled or significant cardiovascular disease\n* Part 1: major surgery within 3 weeks before initiating treatment\n* Part 1: Have received prior radiotherapy within 2 weeks of start of study treatment\n* Part 2 (H&N cancer):\n* Have received prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).\n* Have received prior chemotherapy administered in the recurrent advanced or metastatic setting (except for systemic therapy completed > 6 months prior to screening if given as part of multimodal treatment for locally advanced disease)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Have measurable disease, per RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Have measurable disease, per RECIST v1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part 1G (NSCLC):",
            "criterions": [
                {
                    "exact_snippets": "NSCLC",
                    "criterion": "non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are eligible to receive anti-PD(L)1 therapy combined with chemotherapy in first line metastatic setting",
            "criterions": [
                {
                    "exact_snippets": "eligible to receive anti-PD(L)1 therapy combined with chemotherapy in first line metastatic setting",
                    "criterion": "eligibility for anti-PD(L)1 therapy combined with chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment setting",
                            "expected_value": "first line metastatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have adequate organ functions",
            "criterions": [
                {
                    "exact_snippets": "adequate organ functions",
                    "criterion": "organ functions",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part 1A/1B/1C/1D/1E/1F: Have histologically or cytologically confirmed advanced or metastatic solid tumor for whom no standard treatment with survival benefit is available",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed advanced or metastatic solid tumor",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no standard treatment with survival benefit is available",
                    "criterion": "standard treatment with survival benefit",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have histologically or cytologically confirmed recurrent advanced or metastatic head and neck squamous cell carcinoma considered incurable by local therapies",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        },
                        {
                            "requirement_type": "confirmation_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recurrent advanced or metastatic head and neck squamous cell carcinoma",
                    "criterion": "head and neck squamous cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "recurrent",
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "considered incurable by local therapies",
                    "criterion": "curability by local therapies",
                    "requirements": [
                        {
                            "requirement_type": "curability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "Grade"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PD-L1 status positive",
            "criterions": [
                {
                    "exact_snippets": "PD-L1 status positive",
                    "criterion": "PD-L1 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a histologically confirmed or cytologically confirmed previously untreated stage IV OR stage III not amenable to curative chemoradiotherapy or surgery (AJCC 8th edition) nonsquamous NSCLC OR squamous NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed or cytologically confirmed",
                    "criterion": "NSCLC diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "previously untreated",
                    "criterion": "prior treatment for NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "stage IV OR stage III not amenable to curative chemoradiotherapy or surgery (AJCC 8th edition)",
                    "criterion": "NSCLC stage and treatment amenability",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "stage IV",
                                "stage III"
                            ]
                        },
                        {
                            "requirement_type": "amenability to curative chemoradiotherapy or surgery",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nonsquamous NSCLC OR squamous NSCLC",
                    "criterion": "NSCLC histology subtype",
                    "requirements": [
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": [
                                "nonsquamous",
                                "squamous"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part 2 (H&N cancer)",
            "criterions": [
                {
                    "exact_snippets": "H&N cancer",
                    "criterion": "head and neck cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provide a signed written informed consent for the trial",
            "criterions": [
                {
                    "exact_snippets": "Provide a signed written informed consent for the trial",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed and written",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provided for the trial",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Have a history of Grade ≥ 2 pneumonitis, active autoimmune disease, or persistent immune-mediated toxicity caused by immune checkpoint inhibitor therapy of Grade ≥ 2",
            "criterions": [
                {
                    "exact_snippets": "history of Grade ≥ 2 pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "persistent immune-mediated toxicity caused by immune checkpoint inhibitor therapy of Grade ≥ 2",
                    "criterion": "immune-mediated toxicity caused by immune checkpoint inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have uncontrolled or significant cardiovascular disease",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled or significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part 2 (H&N cancer):",
            "criterions": [
                {
                    "exact_snippets": "H&N cancer",
                    "criterion": "head and neck cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part 1: Have received prior radiotherapy within 2 weeks of start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Have received prior radiotherapy within 2 weeks of start of study treatment",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before start of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.",
            "criterions": [
                {
                    "exact_snippets": "toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible",
                    "criterion": "toxicity related to prior anti-cancer therapy and/or surgery",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "not alopecia"
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "not resolved",
                                "not returned to baseline",
                                "not Grade 1",
                                "not deemed irreversible"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have known CNS metastases unless previously treated and well controlled for at least 1 month",
            "criterions": [
                {
                    "exact_snippets": "known CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unless previously treated and well controlled for at least 1 month",
                    "criterion": "CNS metastases (if present)",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": "previously treated"
                        },
                        {
                            "requirement_type": "disease_control",
                            "expected_value": "well controlled"
                        },
                        {
                            "requirement_type": "duration_of_control",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have known primary CNS cancer.",
            "criterions": [
                {
                    "exact_snippets": "Have known primary CNS cancer.",
                    "criterion": "primary CNS cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have concomitant second malignancies unless a complete remission was achieved at least 2 years before study entry",
            "criterions": [
                {
                    "exact_snippets": "Have concomitant second malignancies unless a complete remission was achieved at least 2 years before study entry",
                    "criterion": "concomitant second malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "remission_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received prior chemotherapy administered in the recurrent advanced or metastatic setting (except for systemic therapy completed > 6 months prior to screening if given as part of multimodal treatment for locally advanced disease)",
            "criterions": [
                {
                    "exact_snippets": "Have received prior chemotherapy administered in the recurrent advanced or metastatic setting",
                    "criterion": "prior chemotherapy in recurrent advanced or metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "history of administration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for systemic therapy completed > 6 months prior to screening if given as part of multimodal treatment for locally advanced disease",
                    "criterion": "systemic therapy as part of multimodal treatment for locally advanced disease",
                    "requirements": [
                        {
                            "requirement_type": "completion time before screening",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "treatment context",
                            "expected_value": "multimodal treatment for locally advanced disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).",
            "criterions": [
                {
                    "exact_snippets": "Have received prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
                    "criterion": "prior immunotherapy with immune checkpoint inhibitors or T-cell co-stimulation targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug classes",
                            "expected_value": [
                                "anti-PD-1 antibody",
                                "anti-PD-L1 antibody",
                                "anti-PD-L2 antibody",
                                "anti-CD137 antibody",
                                "anti-CTLA-4 antibody",
                                "ipilimumab",
                                "any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received any anti-cancer therapy within 4 weeks prior to the first dose",
            "criterions": [
                {
                    "exact_snippets": "Have received any anti-cancer therapy within 4 weeks prior to the first dose",
                    "criterion": "anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received a live vaccine within 30 days prior to the first dose",
            "criterions": [
                {
                    "exact_snippets": "Have received a live vaccine within 30 days prior to the first dose",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part 1: major surgery within 3 weeks before initiating treatment",
            "criterions": [
                {
                    "exact_snippets": "major surgery within 3 weeks before initiating treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}